Dendreon makes Provenge, a personalized immunotherapy for prostate cancer that attracted a lot of hype when it was approved by the FDA in 2010 but never quite caught fire in the oncology community. Valeant will pay down debt with those proceeds as well. Chipping away at its enormous debt load and fixing its lagging dermatology business are key to a turnaround plan Valeant began last year, and the company still has a long way to go.